Literature DB >> 32516053

Persistent Disparities in Cervical Cancer Screening Uptake: Knowledge and Sociodemographic Determinants of Papanicolaou and Human Papillomavirus Testing Among Women in the United States.

Nicole L Johnson1, Katharine J Head1, Susanna Foxworthy Scott2, Gregory D Zimet3.   

Abstract

OBJECTIVES: Cervical cancer is the second-most common type of cancer among women aged 15-44, and racial, ethnic, and economic disparities exist in survival rates despite widely available screening tests and early treatment options. The objective of this study was to describe the association among knowledge, sociodemographic characteristics, and cervical cancer screening, with the goal of developing interventions to prevent cervical cancer in populations at risk of the disease.
METHODS: In 2017, we conducted a nationwide survey of women in the United States aged ≥18 who had ever received a Papanicolaou (Pap) test (N = 630). We conducted t tests and one-way analysis of variance to determine sociodemographic differences (age, education, race, ethnicity, income, type of health insurance) in knowledge about cervical cancer screening (Pap test and human papillomavirus [HPV] test). We used logistic regressions to define significant determinants of cervical cancer screening behaviors in the previous 5 years.
RESULTS: Of 629 respondents, 407 (64.7%) had an annual household income <$30 000, and 322 of 536 (60.1%) respondents had government-provided health insurance. Of 630 women who had ever had a Pap test, 425 (67.5%) had an HPV test. Hispanic and non-Hispanic white women were more likely than Hispanic and non-Hispanic black women (odds ratio [OR] = 2.49; 95% CI, 1.12-4.54; P = .02) and women with government-provided health insurance (OR = 1.91; 95% CI, 1.08-3.37; P = .03) were more likely than women with private health insurance to have received a Pap test in the previous 5 years. Knowledge of HPV was a significant predictor of having received an HPV test in the previous 5 years (OR = 1.37; 95% CI, 1.22-1.54; P < .001).
CONCLUSION: Disparities in cervical cancer screening among sociodemographic groups of women suggest the need for targeted interventions to improve knowledge about Pap and HPV tests.

Entities:  

Keywords:  HPV knowledge; Pap test knowledge; cervical cancer screening; high-risk populations; human papillomavirus (HPV)

Mesh:

Year:  2020        PMID: 32516053      PMCID: PMC7383763          DOI: 10.1177/0033354920925094

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  16 in total

1.  College students' knowledge of human papillomavirus and effectiveness of a brief educational intervention.

Authors:  E C Lambert
Journal:  J Am Board Fam Pract       Date:  2001 May-Jun

2.  The ACA: implications for the accessibility and quality of breast and cervical cancer prevention and treatment services.

Authors:  Sara Rosenbaum
Journal:  Public Health Rep       Date:  2012 May-Jun       Impact factor: 2.792

3.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Authors:  Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A R Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein
Journal:  Obstet Gynecol       Date:  2015-02       Impact factor: 7.661

4.  National assessment of HPV and Pap tests: Changes in cervical cancer screening, National Health Interview Survey.

Authors:  Meg Watson; Vicki Benard; Jessica King; Anatasha Crawford; Mona Saraiya
Journal:  Prev Med       Date:  2017-05-11       Impact factor: 4.018

5.  Human papillomavirus, genital warts, Pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women.

Authors:  R M Mays; G D Zimet; Y Winston; R Kee; J Dickes; L Su
Journal:  Health Care Women Int       Date:  2000 Jul-Aug

6.  Adolescent and young adult women's misunderstanding of the term Pap smear.

Authors:  Diane R Blake; Brittany M Weber; Kenneth E Fletcher
Journal:  Arch Pediatr Adolesc Med       Date:  2004-10

7.  A community approach to addressing excess breast and cervical cancer mortality among women of African descent in Boston.

Authors:  JudyAnn Bigby; Linda K Ko; Natacha Johnson; Michele M A David; Barbara Ferrer
Journal:  Public Health Rep       Date:  2003 Jul-Aug       Impact factor: 2.792

Review 8.  Cervical cancer prevention: new tools and old barriers.

Authors:  Isabel C Scarinci; Francisco A R Garcia; Erin Kobetz; Edward E Partridge; Heather M Brandt; Maria C Bell; Mark Dignan; Grace X Ma; Jane L Daye; Philip E Castle
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

9.  Knowledge, beliefs, and attitudes related to human papillomavirus infection and vaccination, pap tests, and cervical intraepithelial neoplasia among adolescent girls and young women.

Authors:  Shalanda A Bynum; Marcie S Wright; Heather M Brandt; Judith T Burgis; Janice L Bacon
Journal:  J S C Med Assoc       Date:  2009-12

10.  Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014.

Authors:  Meg Watson; Vicki Benard; Elaine W Flagg
Journal:  Prev Med Rep       Date:  2018-02-02
View more
  13 in total

1.  Clinical Significance and Prognostic Value of Lactate Dehydrogenase Expression in Cervical Cancer.

Authors:  Yuping Ye; Min Chen; Xinyan Chen; Jingyu Xiao; Lin Liao; Faquan Lin
Journal:  Genet Test Mol Biomarkers       Date:  2022-03

2.  HPV Testing Behaviors and Willingness to Use HPV Self-sampling at Home Among African American (AA) and Sub-Saharan African Immigrant (SAI) Women.

Authors:  Adebola Adegboyega; Amanda T Wiggins; Lovoria B Williams; Mark Dignan
Journal:  J Racial Ethn Health Disparities       Date:  2021-11-15

3.  Explaining socioeconomic inequality in cervical cancer screening uptake in Malawi.

Authors:  Gowokani Chijere Chirwa
Journal:  BMC Public Health       Date:  2022-07-18       Impact factor: 4.135

4.  Trends and Determinants in Uptake of Cervical Cancer Screening in Spain: An Analysis of National Surveys from 2017 and 2020.

Authors:  Silvia Portero de la Cruz; Jesús Cebrino
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

5.  Awareness of HPV Testing and Acceptability of Self-sampling for Cervical Cancer Screening Among Women in Minnesota.

Authors:  Xuan Zhu; Kathy L MacLaughlin; Chun Fan; Debra J Jacobson; Gregory D Jenkins; Robert M Jacobson; Lila J Finney Rutten
Journal:  J Gen Intern Med       Date:  2021-05-13       Impact factor: 6.473

6.  Understanding cervical cancer after the age of routine screening: Characteristics of cases, treatment, and survival in the United States.

Authors:  Katie E Lichter; Kimberly Levinson; Anne Hammer; Melissa H Lippitt; Anne F Rositch
Journal:  Gynecol Oncol       Date:  2022-02-01       Impact factor: 5.482

7.  "We're Not Taken Seriously": Describing the Experiences of Perceived Discrimination in Medical Settings for Black Women.

Authors:  Ariel Washington; Jill Randall
Journal:  J Racial Ethn Health Disparities       Date:  2022-03-03

8.  Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions.

Authors:  Emily A Burger; Inge M C M de Kok; James F O'Mahony; Matejka Rebolj; Erik E L Jansen; Daniel D de Bondt; James Killen; Sharon J Hanley; Alejandra Castanon; Jane J Kim; Karen Canfell; Megan A Smith; Mary Caroline Regan
Journal:  medRxiv       Date:  2022-07-25

9.  Sociodemographic factors associated with HPV awareness/knowledge and cervical cancer screening behaviors among caregivers in the U.S.

Authors:  Jiyeong Kim; Melanie S Dove; Julie H T Dang
Journal:  BMC Womens Health       Date:  2022-08-08       Impact factor: 2.742

10.  Racial differences in no-show rates for screening mammography.

Authors:  Whitney L Hensing; Steven P Poplack; Cheryl R Herman; Siobhan Sutcliffe; Graham A Colditz; Foluso O Ademuyiwa
Journal:  Cancer       Date:  2021-04-01       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.